These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 22974728)
1. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J Int J Cardiol; 2013 Apr; 165(1):204-6. PubMed ID: 22974728 [No Abstract] [Full Text] [Related]
2. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
3. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151 [TBL] [Abstract][Full Text] [Related]
4. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903 [TBL] [Abstract][Full Text] [Related]
5. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome. Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664 [TBL] [Abstract][Full Text] [Related]
6. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome]. Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670 [TBL] [Abstract][Full Text] [Related]
7. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746 [TBL] [Abstract][Full Text] [Related]
8. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Frére C; Cuisset T; Gaborit B; Alessi MC; Hulot JS J Thromb Haemost; 2009 Aug; 7(8):1409-11. PubMed ID: 19496924 [No Abstract] [Full Text] [Related]
9. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300 [TBL] [Abstract][Full Text] [Related]
11. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Wu H; Qian J; Sun A; Wang Q; Ge J Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905 [TBL] [Abstract][Full Text] [Related]
12. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793 [TBL] [Abstract][Full Text] [Related]
13. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042 [TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970 [TBL] [Abstract][Full Text] [Related]
15. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel]. Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044 [TBL] [Abstract][Full Text] [Related]
16. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
17. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611 [TBL] [Abstract][Full Text] [Related]
18. Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. Amoah V; Storey RF; Worrall AP; Goodridge K; Lovatt T; Smallwood A; Armesilla AL; Nevill AM; Cotton JM Platelets; 2013; 24(8):643-8. PubMed ID: 23148794 [TBL] [Abstract][Full Text] [Related]
19. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Brackbill ML; Kidd RS; Abdoo AD; Warner JG; Harralson AF Heart Vessels; 2009 Mar; 24(2):73-8. PubMed ID: 19337788 [TBL] [Abstract][Full Text] [Related]
20. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ; J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]